10-Q Filing

AIM IMMUNOTECH INC. CIK: 946644 Q1 2016

Filing Information

Form Type	10-Q
Accession Number	`0001615774-16-005470`
Period End Date	20160331
Filing Date	20160516
Fiscal Year	2016
Fiscal Period	Q1
XBRL Instance	heb-20160331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 61 Income Statement 34 Cash Flow Statement 48 Stockholders Equity 8

Balance Sheet 61 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.01M	USD	Point-in-time
Preferred stock, issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.12M	USD	Point-in-time
Preferred stock, issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.16M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.94M	USD	Point-in-time
Preferred stock, outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Marketable securities	`AvailableForSaleSecuritiesCurrent`	$6.84M	USD	Point-in-time
Preferred stock, outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Marketable securities	`AvailableForSaleSecuritiesCurrent`	$6.79M	USD	Point-in-time
Inventory-work in process	`InventoryWorkInProcess`	$1.33M	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Inventory-work in process	`InventoryWorkInProcess`	$1.33M	USD	Point-in-time
Inventory-work in process	`InventoryWorkInProcess`	-	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, authorized	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$335.00K	USD	Point-in-time
Common stock, authorized	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$363.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$9.54M	USD	Point-in-time
Common stock, issued	`CommonStockSharesIssued`	247.57M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$10.57M	USD	Point-in-time
Common stock, issued	`CommonStockSharesIssued`	247.56M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$10.94M	USD	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	247.57M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$11.24M	USD	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	247.56M	shares	Point-in-time
Patent and trademark rights, net	`FiniteLivedIntangibleAssetsNet`	$893.00K	USD	Point-in-time
Patent and trademark rights, net	`FiniteLivedIntangibleAssetsNet`	$862.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$132.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$134.00K	USD	Point-in-time
Total assets	`Assets`	$22.80M	USD	Point-in-time
Total assets	`Assets`	$21.50M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.21M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.40M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$1.22M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$1.70M	USD	Point-in-time
Current portion of capital lease	`CapitalLeaseObligationsCurrent`	$1.00K	USD	Point-in-time
Current portion of capital lease	`CapitalLeaseObligationsCurrent`	-	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$3.09M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.43M	USD	Point-in-time
Commitments and contingencies (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, par value $0.01 per share, authorized 5,000,000; issued and outstanding; none	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, par value $0.01 per share, authorized 5,000,000; issued and outstanding; none	`PreferredStockValue`	-	USD	Point-in-time
Common stock, par value $0.001 per share, authorized 350,000,000 shares; issued and outstanding 247,571,887 and 247,559,487, respectively	`CommonStockValue`	$247.00K	USD	Point-in-time
Common stock, par value $0.001 per share, authorized 350,000,000 shares; issued and outstanding 247,571,887 and 247,559,487, respectively	`CommonStockValue`	$247.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$313.27M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$313.22M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$50.00K	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$-97.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-295.16M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-293.00M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$18.41M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$20.37M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$22.80M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$21.50M	USD	Point-in-time

Income Statement 34 line items

Line Item	Tag	Value	Unit	Period
Clinical treatment programs	`HealthCareOrganizationRevenue`	$39.00K	USD	1 Quarter
Clinical treatment programs	`HealthCareOrganizationRevenue`	$36.00K	USD	1 Quarter
Total revenues	`SalesRevenueNet`	$36.00K	USD	1 Quarter
Total revenues	`SalesRevenueNet`	$39.00K	USD	1 Quarter
Production costs	`ManufacturingCosts`	$372.00K	USD	1 Quarter
Production costs	`ManufacturingCosts`	$268.00K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$2.67M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.00M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$1.91M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$2.45M	USD	1 Quarter
Total costs and expenses	`CostsAndExpenses`	$4.96M	USD	1 Quarter
Total costs and expenses	`CostsAndExpenses`	$3.72M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-3.68M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-4.92M	USD	1 Quarter
Interest expense	`InterestExpense`	$2.00K	USD	1 Quarter
Interest expense	`InterestExpense`	-	USD	1 Quarter
Interest and other income	`InterestAndOtherIncome`	$61.00K	USD	1 Quarter
Interest and other income	`InterestAndOtherIncome`	$106.00K	USD	1 Quarter
Loss on sales of short term marketable securities	`MarketableSecuritiesGainLoss`	$-107.00K	USD	1 Quarter
Loss on sales of short term marketable securities	`MarketableSecuritiesGainLoss`	-	USD	1 Quarter
Gain from sale of income tax net operating losses and research credits	`GainFromSaleOfIncomeTaxOperatingLosses`	$-1.56M	USD	1 Quarter
Gain from sale of income tax net operating losses and research credits	`GainFromSaleOfIncomeTaxOperatingLosses`	$-1.37M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-2.16M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-3.44M	USD	1 Quarter
Reclassification adjustments for loss on sales of short term marketable securities included in net loss	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$107.00K	USD	1 Quarter
Reclassification adjustments for loss on sales of short term marketable securities included in net loss	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	-	USD	1 Quarter
Unrealized gain on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$40.00K	USD	1 Quarter
Unrealized gain on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$111.00K	USD	1 Quarter
Net comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-3.33M	USD	1 Quarter
Net comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-2.02M	USD	1 Quarter
Basic and diluted loss per share (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.01	USD	1 Quarter
Basic and diluted loss per share (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	1 Quarter
Weighted average shares outstanding, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	247.56M	shares	1 Quarter
Weighted average shares outstanding, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	213.63M	shares	1 Quarter

Cash Flow Statement 48 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-2.16M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-3.44M	USD	1 Quarter
Depreciation of property and equipment	`Depreciation`	$300.00K	USD	1 Quarter
Depreciation of property and equipment	`Depreciation`	$180.00K	USD	1 Quarter
Amortization and abandonment of patent and trademark rights	`AmortizationAndAbandonmentOfIntagibleAssets`	$30.00K	USD	1 Quarter
Amortization and abandonment of patent and trademark rights	`AmortizationAndAbandonmentOfIntagibleAssets`	$71.00K	USD	1 Quarter
Equity-based compensation	`StockOptionPlanExpense`	$52.00K	USD	1 Quarter
Equity-based compensation	`StockOptionPlanExpense`	$58.00K	USD	1 Quarter
Realized loss on sale of marketable securities	`MarketableSecuritiesRealizedGainLoss`	$-107.00K	USD	1 Quarter
Realized loss on sale of marketable securities	`MarketableSecuritiesRealizedGainLoss`	-	USD	1 Quarter
Inventories	`IncreaseDecreaseInInventories`	$480.00K	USD	1 Quarter
Inventories	`IncreaseDecreaseInInventories`	-	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$28.00K	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$33.00K	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$236.00K	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$182.00K	USD	1 Quarter
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$478.00K	USD	1 Quarter
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$-844.00K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-1.04M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-4.26M	USD	1 Quarter
Purchase of property, equipment and construction in progress	`PaymentsToAcquirePropertyPlantAndEquipment`	-	USD	1 Quarter
Purchase of property, equipment and construction in progress	`PaymentsToAcquirePropertyPlantAndEquipment`	$47.00K	USD	1 Quarter
Lease deposit refund	`DepositsOnCapitalLeasesRefunded`	-	USD	1 Quarter
Lease deposit refund	`DepositsOnCapitalLeasesRefunded`	$2.00K	USD	1 Quarter
Additions to patent and trademark rights	`PaymentsToAcquireIntangibleAssets`	$145.00K	USD	1 Quarter
Additions to patent and trademark rights	`PaymentsToAcquireIntangibleAssets`	$62.00K	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-60.00K	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-192.00K	USD	1 Quarter
Payments on capital leases	`PaymentsOnCapitalLeases`	$1.00K	USD	1 Quarter
Payments on capital leases	`PaymentsOnCapitalLeases`	$7.00K	USD	1 Quarter
Proceeds from sale of stock, net of issuance costs	`ProceedsFromIssuanceOfCommonStock`	$2.00K	USD	1 Quarter
Proceeds from sale of stock, net of issuance costs	`ProceedsFromIssuanceOfCommonStock`	$5.24M	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$5.24M	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$1.00K	USD	1 Quarter
Net increase(decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$786.00K	USD	1 Quarter
Net increase(decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-1.10M	USD	1 Quarter
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$1.01M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$2.12M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$2.16M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$2.94M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$1.01M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$2.12M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$2.16M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$2.94M	USD	Point-in-time
Unrealized gain on marketable securities	`UnrealizedGainLossOnSecurities`	$111.00K	USD	1 Quarter
Unrealized gain on marketable securities	`UnrealizedGainLossOnSecurities`	$147.00K	USD	1 Quarter
Cash paid for interest expense	`InterestPaid`	$2.00K	USD	1 Quarter
Cash paid for interest expense	`InterestPaid`	-	USD	1 Quarter

Stockholders Equity 8 line items

Line Item	Tag	Value	Unit	Period
Balance, at beginning	`StockholdersEquity`	$18.41M	USD	Point-in-time
Balance, at beginning	`StockholdersEquity`	$20.37M	USD	Point-in-time
Equity-based compensation	`StockGrantedDuringPeriodValueSharebasedCompensation`	$52.00K	USD	1 Quarter
Shares sold at the market	`StockIssuedDuringPeriodValueNewIssues`	$2.00K	USD	1 Quarter
Net comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-3.33M	USD	1 Quarter
Net comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-2.02M	USD	1 Quarter
Balance, at end	`StockholdersEquity`	$18.41M	USD	Point-in-time
Balance, at end	`StockholdersEquity`	$20.37M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.